Gastroenterology and Hepatology from Bed to Bench

Vol. 14 No. 1 (2021)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)

Gastroenterology and Hepatology from Bed to Bench, Vol. 14 No. 1 (2021), 26 January 2021
https://doi.org/10.22037/ghfbb.v14i1.1897

Abstract

Neuroendocrine tumors of the gastrointestinal tract and pancreas include a range of rare and diverse neoplasms with unique tumor biology, natural history, and clinical management. Neuroendocrine tumors of the ampulla of Vater are extremely uncommon cancers that account for only about 0.3%-1% of all gastrointestinal neuroendocrine tumors. Approximately 139 cases have been reported to date. In this paper, we describe two patients with low to intermediate grades of ampullary neuroendocrine tumors that underwent multiple courses of chemotherapy with Capecitabine (Xeloda®) and Temozolomide (Temodal®). Our two patients had a dramatic response to this regimen. According to our study, it seems that ampullary neuroendocrine tumors have behavior like pancreatic neuroendocrine tumors which requires further studies in more patients.

Keywords: Neuroendocrine tumors, Vater's ampulla, Capecitabine, Temozolomide.

(Please cite as: Noorali S,  Haghighi Sh. Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®). Gastroenterol Hepatol Bed Bench 2021;14(1):85-88).

Keywords:
  • Neuroendocrine Tumors
  • Vater's Ampulla
  • Capecitabine
  • Temozolomide

How to Cite

Noorali, S., & Haghighi, S. (2021). Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®) . Gastroenterology and Hepatology from Bed to Bench, 14(1). https://doi.org/10.22037/ghfbb.v14i1.1897

References

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-43.

Ricci JL. Carcinoid of the ampulla of Vater. Local resection or pancreaticoduodenectomy. Cancer 1993;71:686-90.

Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, et al. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumors of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015;5:e008248.

Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Theoncologist 2011;16:835-43.

Ho Lee S, Hoon Lee T, Jang SH, Choi ChY, Myung Lee W, Min JH, et al. Ampullary neuroendocrine tumor diagnosed by endoscopic papillectomy in previously confirmed ampullary adenoma. World J Gastroenterol 2016;22:3687-92.

Jayant M, Punia R, Kaushik R, Sharma R, Sachdev A, Nadkarni NK, et al. Neuroendocrine tumors of the ampulla of vater: presentation, pathology and prognosis. JOP 2012;13:263-7.

Odabasi M, Yildiz KM, Cengiz E, Hasan AH, Gunay E, Ozkan E, et al. Treatment of ampullary neuroendocrine tumor by endoscopic snare papillectomy. Am J Case Rep 2013;14:439-43.

Hatzitheoklitos E, Büchler MW, Friess H, Poch B, Ebert M, Mohr W, et al. Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer 1994;73:1580-8.

Waisberg J, Joppert-Netto G, Yonamine RY, Waisberg DR. Neuroendocrine Tumor of the Ampulla of Vater: A Rare Neoplasm in an Atypical Site. Rep Three Cases Rev Lit JOP 2016;17:538-42.

Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management. Arch Surg 2009;144:527-31.

Ofosu A, Taccone M, Potakamuri L, Jagannath S. Ampullary Neuroendocrine Tumor: A Rare Cause of Recurrent Abdominal Pain. Crcm 2014;3:139-44.

Tsukagoshi M, Hosouchi Y, Araki K, Mochida Y, Aihara R, Shirabe K, et al. Neuroendocrine tumor of the ampulla of Vater with distant cystic lymph node metastasis: a case report. Surg Case Rep 2016;2:73.

Abbasi S, Kashashna A, Albaba H. Efficacy of capecitabine and Temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Pancreas 2014;43:1303-5.

Mahjoub AR, O'Reilly EM. Emerging therapies for pancreas neuroendocrine cancers. Chin Clin Oncol 2013;2:23.

Devata S, Kim EJ. Neoadjuvant chemotherapy with capecitabine and Temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 2012;5:622-6.

Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res 2013;6:S10-2.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and Temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75.

Miljković MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 2012;57:9-18.

Yang K, Yun SP, Kim S, Shin N, Park DY, Seo HI. Clinicopathological features and surgical outcomes of neuroendocrine tumors of ampulla of Vater. BMC Gastroenterol 2017;17:70.

  • Abstract Viewed: 55 times
  • PDF Downloaded: 67 times

Download Statastics

Developed By

Open Journal Systems